KZIA
NEUTRALAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Ref P/E, PEG, Graham Number
- Price/Book is relatively moderate at 3.11
- P/S ratio of 53.08 is extreme
- Forward P/E is deeply negative
- No Graham Number available due to lack of earnings
Ref Growth rates
- Triple-digit revenue growth
- Analyst target price is >100% above current price
- High burn rate may necessitate future dilution
Ref Historical trends
- Strong 1-year recovery (+141.6%)
- Devastating 5-year decline (-98.5%)
Ref Altman Z-Score, Piotroski F-Score
- Zero debt
- Current ratio 2.87 indicates good liquidity
- Piotroski F-Score of 4/9 is only marginally stable
- Negative ROE and ROA
Ref Yield, Payout
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for KZIA and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
KZIA
Kazia Therapeutics Limited
Primary
|
-98.5% | -84.8% | +141.6% | +26.4% | +8.8% | +20.2% |
|
IMDX
Insight Molecular Diagnostics Inc.
Peer
|
-97.0% | -53.0% | +9.3% | -18.5% | -39.6% | -15.7% |
|
BDSX
Biodesix, Inc.
Peer
|
-97.8% | -75.2% | -34.9% | +31.6% | +72.1% | +49.0% |
|
DH
Definitive Healthcare Corp.
Peer
|
-97.5% | -89.8% | -57.4% | -66.5% | -13.7% | -13.0% |
|
GOSS
Gossamer Bio, Inc.
Peer
|
-95.6% | -66.2% | -57.8% | -85.5% | -26.7% | +0.4% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
KZIA
Kazia Therapeutics Limited
|
NEUTRAL | $100.79M | - | -106.9% | -% | $8.82 | |
|
IMDX
Insight Molecular Diagnostics Inc.
|
BEARISH | $101.97M | - | -% | -% | $3.17 | Compare |
|
BDSX
Biodesix, Inc.
|
BEARISH | $93.92M | - | -302.6% | -49.3% | $11.74 | Compare |
|
DH
Definitive Healthcare Corp.
|
NEUTRAL | $111.79M | - | -40.4% | -57.5% | $1.07 | Compare |
|
GOSS
Gossamer Bio, Inc.
|
BEARISH | $87.21M | - | -% | -% | $0.37 | Compare |
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning KZIA from our newsroom.